Skip to main content

BIOFIRE® FILMARRAY®  Meningitis/Encephalitis (ME) Panel

1 Test. 14 Targets. ~ 1 Hour.

Make timely and potentially life-saving interventions in meningitis and encephalitis cases with rapid, comprehensive results from this multiplex molecular test. 

Make Every Second Count

Distinguishing bacterial from viral meningitis based on clinical presentation alone is not only challenging, but it can also be a matter of life and death—especially in the younger patients. The BIOFIRE ME Panel tests for a broad grouping of targets for fast, pathogen-specific answers that can help save lives and guide appropriate therapy.

The Power Behind the Panel

The BIOFIRE ME Panel can provide the essential combination of speed, accuracy, and comprehensiveness to enable fast identification of a probable pathogen. 

How the BIOFIRE ME Panel Helps

The BIOFIRE ME Panel accelerates diagnoses, streamlining antimicrobial decisions and improving patient management by reducing hospital stays. Additionally, it enhances pathogen detection for a more comprehensive diagnostic approach.

Reduce Time to Diagnosis 

The BIOFIRE ME Panel can potentially yield an up to four-day reduction in time to diagnosis for adults and children.2,3

Optimize Antimicrobial Decision-Making

Rapid results from the BIOFIRE ME Panel have shown a two-day reduction in acyclovir and antibiotic usage.4,5

Improve Patient Management

Reduce hospital length of stay for adult and pediatric patients by two and three days, respectively.4,6

Detect Pathogens More Often

The BIOFIRE ME Panel can potentially increase the diagnostic yield in adult and pediatric patients 2.9 times and 2.3 times, respectively.6,7

The Meningitis/Encephalitis Testing Menu

Discover the 14 targets on the BIOFIRE ME Panel, including seven viruses, six bacteria, and one yeast associated with community-acquired meningitis and encephalitis. 

Overall 94.2% sensitivity and 99.8% specificity1

Sample Type
Cerebrospinal Fluid (CSF) collected by lumbar puncture 

Syndromic Testing Made Simple

The BIOFIRE® FILMARRAY® Systems run syndromic infectious disease tests. One multiplex assay simultaneously tests for the most common pathogens and antimicrobial resistance genes associated with a particular syndrome.

Learn More About Systems



The BIOFIRE TORCH System uses multiplex PCR technology to simultaneously test for a comprehensive grouping of targets in about an hour. 

  • Compatible with six-panel syndromic portfolio
  • Reduced footprint provides up to six times the throughput per square foot of laboratory bench space
  • Scalable configuration allows customized throughput
  • Simplified workflow features a touchscreen interface and integrated barcode scanner
  • Data management automation includes LIS connectivity and random-access operation


The BIOFIRE 2.0 System enables simplified test ordering, faster turnaround times, and increased accuracy by minimizing manual data entry.

  • Scalable configuration allows customized throughput and efficient use of laboratory bench space
  • Offers LIS connectivity, random-access operation, and single database management of up to 8 instruments per computer

Service & Support

To order the BIOFIRE ME Panel, contact your regional sales representative or use the following contact information:


Phone: 1-801-736-6354

US Sales Extension: 1502

International Sales Extension: 1536

Product Information

BIOFIRE ME Panel Part NumbersRFIT-ASY-011830 Pouch Kit
BIOFIRE ME Panel Part NumbersRFIT-ASY-01196 Pouch Kit

1.     Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Meningitis/Encephalitis Panel, data on file, BioFire Diagnostics.

2.     Cailleaux M., et. al., (2020) Eur J Clin Microbiol. 39(2):293-297.

3.     O’Brien MP., et. al., (2018) Pediatri Infect Dis J. 37(9):868-871.

4.     Moffa MA., et. al., (2020) Antibiotics. 9(6):282.

5.     Hagan, A., et. al., (2020) BMC Pediatr. 20(1):56.

6.     Posnakoglou L., et. al., (2020) Eur J Clin Microbiol Infect Dis. 39(12):2379-2386.

7.     Ena J., et. al., (2021) Intern Emerg Med. 16(5):1289-1295.